Furthermore, we demonstrated that in TNBC and hormone receptor-positive breast cancer, survival differences still exists between SCNA-defined groups, suggesting that these patient groups may provide additional prognostic information to currently defined tumor subtypes. The gene discussed is NR4A1; the disease is neoplasm.